IL17A and rheumatoid arthritis: While recent data on the blockade of IL-17 did not yield results as promising in clinical trials as initially expected (59), it is important to highlight that Th1/Th17 cells have been shown to produce additional inflammatory cytokines such as GM-CSF (60), and it has been recently shown that the blockade of the receptor for this cytokine with mavrilimumab has an effect on improving clinical parameters in patients with RA (61).